These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 25576149)

  • 1. Accelerated formulation development of monoclonal antibodies (mAbs) and mAb-based modalities: review of methods and tools.
    Razinkov VI; Treuheit MJ; Becker GW
    J Biomol Screen; 2015 Apr; 20(4):468-83. PubMed ID: 25576149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-throughput screening and stability optimization of anti-streptavidin IgG1 and IgG2 formulations.
    Alekseychyk L; Su C; Becker GW; Treuheit MJ; Razinkov VI
    J Biomol Screen; 2014 Oct; 19(9):1290-301. PubMed ID: 25023322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formulation development of therapeutic monoclonal antibodies using high-throughput fluorescence and static light scattering techniques: role of conformational and colloidal stability.
    Goldberg DS; Bishop SM; Shah AU; Sathish HA
    J Pharm Sci; 2011 Apr; 100(4):1306-15. PubMed ID: 20960568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advancements in high throughput biophysical technologies: applications for characterization and screening during early formulation development of monoclonal antibodies.
    Samra HS; He F
    Mol Pharm; 2012 Apr; 9(4):696-707. PubMed ID: 22263524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Towards the implementation of quality by design to the production of therapeutic monoclonal antibodies with desired glycosylation patterns.
    del Val IJ; Kontoravdi C; Nagy JM
    Biotechnol Prog; 2010; 26(6):1505-27. PubMed ID: 20665659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening of monoclonal antibody formulations based on high-throughput thermostability and viscosity measurements: design of experiment and statistical analysis.
    He F; Woods CE; Trilisky E; Bower KM; Litowski JR; Kerwin BA; Becker GW; Narhi LO; Razinkov VI
    J Pharm Sci; 2011 Apr; 100(4):1330-40. PubMed ID: 24081468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-Throughput Screening and Analysis of Charge Variants of Monoclonal Antibodies in Multiple Formulations.
    Alekseychyk L; Su C; Becker GW; Treuheit MJ; Razinkov VI
    SLAS Discov; 2017 Sep; 22(8):1044-1052. PubMed ID: 28570837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of High Throughput Screening Techniques to Predict Stability of Monoclonal Antibody Formulations During Early Stage Development.
    Goldberg DS; Lewus RA; Esfandiary R; Farkas DC; Mody N; Day KJ; Mallik P; Tracka MB; Sealey SK; Samra HS
    J Pharm Sci; 2017 Aug; 106(8):1971-1977. PubMed ID: 28456733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic multitechnique approach for detection and characterization of reversible self-association during formulation development of therapeutic antibodies.
    Esfandiary R; Hayes DB; Parupudi A; Casas-Finet J; Bai S; Samra HS; Shah AU; Sathish HA
    J Pharm Sci; 2013 Jan; 102(1):62-72. PubMed ID: 23150484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of a high-throughput relative chemical stability assay to screen therapeutic protein formulations by assessment of conformational stability and correlation to aggregation propensity.
    Rizzo JM; Shi S; Li Y; Semple A; Esposito JJ; Yu S; Richardson D; Antochshuk V; Shameem M
    J Pharm Sci; 2015 May; 104(5):1632-40. PubMed ID: 25757872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 2DE approach for high-throughput antigen separation applicable to mAb production.
    Carta F; Lobina O; Mannu F; Ferru E; Pantaleo A; Orrù M; Turrini F
    Electrophoresis; 2012 Aug; 33(16):2546-52. PubMed ID: 22899262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic multitechnique approach for detection and characterization of reversible self-association during formulation development of therapeutic antibodies.
    Esfandiary R; Hayes DB; Parupudi A; Casas-Finet J; Bai S; Samra HS; Shah AU; Sathish HA
    J Pharm Sci; 2013 Sep; 102(9):3089-99. PubMed ID: 23794522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-throughput assay for measuring monoclonal antibody self-association and aggregation in serum.
    Li X; Geng SB; Chiu ML; Saro D; Tessier PM
    Bioconjug Chem; 2015 Mar; 26(3):520-8. PubMed ID: 25714504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Examination of thermal unfolding and aggregation profiles of a series of developable therapeutic monoclonal antibodies.
    Brader ML; Estey T; Bai S; Alston RW; Lucas KK; Lantz S; Landsman P; Maloney KM
    Mol Pharm; 2015 Apr; 12(4):1005-17. PubMed ID: 25687223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An automated robotic platform for rapid profiling oligosaccharide analysis of monoclonal antibodies directly from cell culture.
    Doherty M; Bones J; McLoughlin N; Telford JE; Harmon B; DeFelippis MR; Rudd PM
    Anal Biochem; 2013 Nov; 442(1):10-8. PubMed ID: 23872006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The emerging role of biosensor-based epitope binning and mapping in antibody-based drug discovery.
    Ditto NT; Brooks BD
    Expert Opin Drug Discov; 2016 Oct; 11(10):925-37. PubMed ID: 27600831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-throughput screening of formulations to optimize the thermal stability of a therapeutic monoclonal antibody.
    Niedziela-Majka A; Kan E; Weissburg P; Mehra U; Sellers S; Sakowicz R
    J Biomol Screen; 2015 Apr; 20(4):552-9. PubMed ID: 25385011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality by design: impact of formulation variables and their interactions on quality attributes of a lyophilized monoclonal antibody.
    Awotwe-Otoo D; Agarabi C; Wu GK; Casey E; Read E; Lute S; Brorson KA; Khan MA; Shah RB
    Int J Pharm; 2012 Nov; 438(1-2):167-75. PubMed ID: 22944306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-throughput process development for biopharmaceutical drug substances.
    Bhambure R; Kumar K; Rathore AS
    Trends Biotechnol; 2011 Mar; 29(3):127-35. PubMed ID: 21255855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploiting mAb structure characteristics for a directed QbD implementation in early process development.
    Karlberg M; von Stosch M; Glassey J
    Crit Rev Biotechnol; 2018 Sep; 38(6):957-970. PubMed ID: 29514519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.